Skip to main content

Advertisement

SpringerLink
Log in

CASE REPORT: Normalization of Markedly Elevated α-Fetoprotein in a Virologic Nonresponder with HCV-Related Cirrhosis

  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCES

  1. Simonetti RG, Camma C, Fiorello F, et al: Hepatitis C virus infection as a risk factor for hepatocellular carcinoma in patients with cirrhosis: a case control study. Ann Intern Med 1166:97–102

  2. Yu MW, You SL, Chang AS, et al: Association between hepatitis C virus antibodies and hepatocellular carcinoma in Taiwan. Cancer Res 51:5621–5662, 1999

    Google Scholar 

  3. Ikeda K, Saitoh S, Koida I: A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology 18:47–53, 1993

    Google Scholar 

  4. Peng YC, Chan CS, Chen GH: The effectiveness of serum α-fetoprotein level in anti-HCV positive patients for screening hepatocellular carcinoma. Hepato-Gastroenterol 46:3208–3211, 1999

    Google Scholar 

  5. Fook-Hong N, Kai-Chiu C, Chi-Sing C, et al: High α-fetoprotein level in HCV-related nodular liver cell dysplasia. Am J Gastroenterol 94:2296–2297, 1999

    Google Scholar 

  6. Okuda K: Clinical aspects of hepatocellular carcinoma: analysis of 134 cases. In K, Okuda RL, Peters (eds). Hepatocellular Carcinoma. New York, John Wiley & Sons, 1976, p 387

    Google Scholar 

  7. Kew MC, Newburne PM: Tumor markers in hepatocellular carcinoma. In K Okuda, IR Mackay (eds). Hepatocellular Carcinoma. Geneva, Unione Internationale Contre le Cancer, 1982, p 123

    Google Scholar 

  8. Okuda K, et al: Clinical observations during a relatively early stage of hepatocellular carcinoma, with special reference to serum α-fetoprotein levels. Gastroenterology 69:226, 1975

    Google Scholar 

  9. Ebara M, et al: Natural history of minute hepatocellular carcinoma smaller than three centimeters complicating cirrhosis: a study in 22 patients. Gastroenterology 90:289, 1986

    Google Scholar 

  10. Shinagawa T, et al: Diagnosis and clinical features of small hepatocellular carcinoma with emphasis of the utility of realtime ultrasonography: a study of 51 patients. Gastroenterology 86:495, 1984

    Google Scholar 

  11. Taketa K: α-Fetoprotein: reevaluation in hepatology. Hepatology 12:1420, 1990

    Google Scholar 

  12. Chen DS, Sung JL: Serum alpha-fetoprotein in hepatocellular carcinoma. Cancer 40:779–783, 1977

    Google Scholar 

  13. Kato Y, Nakata K, Omagari K, et al: Risk of hepatocellular carcinoma in patients with cirrhosis in Japan: analysis of infectious hepatitis viruses. Cancer 74:2234–2238, 1994

    Google Scholar 

  14. Takano S, Yokosuka O, Imazeki F, et al: Incidence of hepatocellular carcinoma in chronic hepatitis B and C: a prospective study of 251 patients. Hepatology 21:650–655, 1995

    Google Scholar 

  15. Yamada G, Tanaka E, Miura T, et al: Epidemiology of genotypes of hepatitis C virus in Japanese patients with type C chronic liver diseases: multi-institution analysis. J Gastroenterol Hepatol 10:538–545, 1995

    Google Scholar 

  16. DiBisceglie AM: Hepatitis C and hepatocellular carcinoma. Semin Liver Dis 15:64–69, 1995

    Google Scholar 

  17. Weinberg DS, Malet PF: Chronic hepatitis C and markedly elevated serum α-fetoprotein: complete response to treatment with α-interferon. Am J Gastroenterology 89:1253–1254, 1994

    Google Scholar 

  18. McHutchinson JG, Gordon S, Schiff ER, et al: Interferon alfa 2b montherapy versus interferon alfa 2b plus ribavirin as initial treatment for chronic hepatitis C: results of a US multicenter randomized controlled trial. N Engl J Med 339:1485–1492, 1998

    Google Scholar 

  19. Shiffman ML, Hofmann CH, Luketic VA, et al: Gradual reduction in interferon dose reduces the incidence of relapse in patients with chronic hepatitis C: results of a randomized controlled trial. Hepatology 24:21–6, 1996

    Google Scholar 

  20. Davis GL, Balart LA, Schiff ER, et al: Treatment of chronic hepatitis C with recombinant interferon alpha: a multicenter randomized controlled trial. N Engl J Med 321:1501–6, 1989

    Google Scholar 

  21. DiBisceglie AM, Martin P, Kassianides C, et al: Recombinant interferon alfa therapy for chronic hepatitis C. N Engl J Med 321:1506–10, 1989

    Google Scholar 

  22. Marcellin P, Boyer N, Giostra E, et al: Recombinant alphainterferon in patients with chronic non-A, non-B hepatitis: a multicenter randomized controlled trial from France. Hepatology 13:393–7, 1991

    Google Scholar 

  23. Causse X, Godinot H, Chevallier M, et al: Comparison of 1 or 3 mU of interferon alpha-2b and placebo in patients with chronic non-A, non-B hepatitis. Gastroenterology 101:497–502, 1991

    Google Scholar 

  24. Chemello L, Bonetti P, Cavalletto L, et al: Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C. Hepatology 22:700–6, 1995

    Google Scholar 

  25. Poynard T, Bedossa P, Chevallier M, et al: A comparison of three interferon alfa-2b regimens for the long-tern treatment of chronic non-A, non-B hepatitis. N Engl J Med 332:1457–62, 1995

    Google Scholar 

  26. Shiffman ML, Hofmann CM, Thompson EB, et al: Relationship between biochemical; virologic and histologic response during interferon treatment of chronic hepatitis C. Hepatology 26:780–5, 1997

    Google Scholar 

  27. Shiffman ML, Hofmann CM, Contos MJ, et al: A randomized controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia. Gastroenterology 117:1164–72, 1999

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hepatology Division, Department of Gastroenterology, St. Barnabas Hospital, Weill Medical College of Cornell University, Bronx, New York, USA

    David F. Stein & Malay Myaing

Authors
  1. David F. Stein
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Malay Myaing
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Stein, D.F., Myaing, M. CASE REPORT: Normalization of Markedly Elevated α-Fetoprotein in a Virologic Nonresponder with HCV-Related Cirrhosis. Dig Dis Sci 47, 2686–2690 (2002). https://doi.org/10.1023/A:1021044803279

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1021044803279

Search

Navigation